LifeWatch Services Inc. Launches Next-Generation LifeStar ACT III Platinum

Tue Sep 30, 2008 12:30pm EDT

* Reuters is not responsible for the content in this press release.

CHICAGO--(Business Wire)--
LifeWatch Corp.:

   --  Wireless 3-channel ECG monitor with ST deviation analysis for
        enhanced real-time monitoring

   --  ACT III Platinum will allow expansion into alternative patient
        monitoring programs

   --  LifeWatch poised to further drive revenues following launch

   Card Guard AG (SWX Swiss Exchange:CARDG), the parent company of
LifeWatch Corp. announced today that LifeWatch has launched its
next-generation LifeStar ACT III Platinum (ACT III) monitor in the
United States. This advanced monitoring device, cleared by the FDA in
June 2008, provides enhanced heart arrhythmia detection through its
3-channel ECG functionality and ST deviation analysis that can measure
ischemic changes. The ACT III monitor automatically detects and sends
heart rhythm abnormalities to a 24/7 LifeWatch monitoring call center.
This call center is staffed by certified cardiac technicians, who
interpret the data and initiate physician notification based on
pre-determined criteria. The ACT III monitor, which requires only
minimal patient intervention, significantly improves patient
compliance and increases diagnostic yield.

   Higher sensitivity facilitates expansion into alternative patient
monitoring markets

   The ACT III monitor offers broader functionality with its
high-performance multi-channel Ambulatory Cardiac Telemetry in one
simple-to-use system. With up to 21-days of real-time ECG monitoring
and the provision of ST deviation analysis, the ACT III provides more
sensitive and specific data for initial or early detection of
arrhythmia in patients that have limited or atypical symptoms. The
device has 6 hours of memory in the sensor and a flash memory of up to
21 days of data on the ACT Cell phone monitor. This ensures that no
valuable data is lost if a patient is disconnected from the cellular
phone. The sophisticated algorithm and advanced wireless and web-based
technologies of ACT III enhances data collection, analysis,
transmission and reporting, and can be utilized in standard and
alternative patient monitoring programs, such as Specialized Atrial
Fibrillation (AF) Patient Care and Congestive Heart Failure (CHF)

   "In my opinion, real-time outpatient cardiac monitoring using this
new and unique 3-channel configuration will extend physicians
management of patient conditions which have been traditionally
monitored in an inpatient setting. Disease state management requires
more accurate diagnostic tools such as the ACT III to allow for early
detection of a worsening condition in patients that are minimally
symptomatic" according to Dr. Harry A. Kopelman, Director of the
Cardiac Electrophysiology Laboratory at the Fuqua Heart Center & the
Piedmont Heart Institute. Dr. Kopelman is a highly esteemed
electrophysiologist who has authored and co-authored a number of
papers in highly referred publications and serves as the Chairman of
the LifeWatch Medical Advisory Board. Biography of Dr. Harry Kopelman

   LifeStar ACT, which was launched in January of 2007, is the
catalyst for the rapid growth in LifeWatch's revenues. This
exceptional growth is directly attributed to the successful adoption
of the ACT monitoring system in hospitals, cardiology practices, and
electrophysiology labs. Forty-five percent of the top U.S. Cardiac
Centers (US News and World Report), utilize the LifeStar ACT System in
their monitoring programs, while over 20 key cardiac institutions have
enrolled their AF catheter and surgical ablation patients in the
first-to-market LifeWatch AF Patient Care Program. This unique program
provides objective post-operative arrhythmia analysis that
dramatically improves a physician's ability to assess the clinical
outcomes from these complex procedures.

   LifeWatch is in the process of increasing the number of its sales
force to support the aggressive growth with ACT I and ACT III.

   About LifeWatch Corp.:

   LifeWatch Corp., through its operating subsidiaries Lifewatch
Services, Inc. and LifeWatch Technologies, Inc. (Instromedix) is an
independent provider of ambulatory cardiac monitoring services and a
manufacturer and distributor of ambulatory cardiac and vital signs
monitoring devices in the United States. Its current services are used
by physicians primarily to monitor patients who are suspected of
having heart rhythm disorders, or cardiac arrhythmias, and its
products are used by itself and by others in connection with providing
cardiac monitoring services. LifeWatch is a wholly owned subsidiary of
Card Guard AG, a leading healthcare technology and solutions provider
listed on the Swiss Stock Exchange (CARDG). For more information,

LifeWatch Corp.
Brent Atwood
Tel: 847 774 9846

Copyright Business Wire 2008